New research suggests cystic fibrosis transmembrane conductance regulator (CFTR) modulators may provide mental health benefits for pediatric patients and their caregivers early in treatment.
RT’s Three Key Takeaways:
- Reduced Anxiety Burden: Children receiving cystic fibrosis transmembrane conductance regulator (CFTR) modulators showed significantly lower anxiety scores than those not receiving the therapy.
- Caregiver Mental Health: Parents of children on modulator therapy reported lower levels of depression and anxiety, suggesting the treatment’s impact extends to the family’s emotional well-being.
- Ongoing Screening Requirements: Researchers noted that despite improved clinical outcomes from disease-modifying therapies, healthcare providers should continue mental health screening for the cystic fibrosis community.
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators may offer mental health benefits for children with cystic fibrosis and their parents, according to prospective observational findings published in European Journal of Pediatrics. The study points to lower anxiety scores in treated children and lower anxiety and depression scores among their caregivers.
The study evaluated 53 children with cystic fibrosis, including 24 using modulator therapy and 29 not using the treatment, along with their parents. Investigators found no significant demographic differences between the groups, which supported the comparison of mental health and quality of life measures across treatment status.
Children in the study completed the Cystic Fibrosis Quality of Life Questionnaire Revised, the Children’s Depression Inventory, and the Screen for Child Anxiety Related Emotional Disorders. Parents completed the Beck Depression Inventory, the Beck Anxiety Inventory, and the World Health Organization Quality of Life Scale Short Form.
Children who were not receiving CFTR modulators had significantly higher anxiety scores on the Screen for Child Anxiety Related Emotional Disorders than those receiving therapy. This finding suggests that modulator use may be associated with a reduced anxiety burden early in treatment, although the researchers noted the observational design means causality cannot be established.
The psychosocial benefits also extended to caregivers. Parents of children who were not using CFTR modulators had significantly higher depression and anxiety scores on the Beck Depression Inventory and Beck Anxiety Inventory compared with parents of children receiving modulator therapy.
Quality of life scores among parents were higher in the modulator therapy group, but this difference did not reach statistical significance. Together, the results suggest that the early benefits of CFTR modulators may extend beyond clinical symptoms, potentially reducing emotional strain for both children and caregivers, the study authors said.
The findings underscore the need for continued mental health screening in cystic fibrosis care, even as disease-modifying therapy improves clinical outcomes. Larger longitudinal studies are needed to determine whether CFTR modulators directly improve anxiety, depression, and quality of life over time.
Reference
Yetişgin H et al. Early effect of CFTR modulators on the mental health of patients with cystic fibrosis and parents. Eur J Pediatr. 2026;185:464.
This article was originally published by AMJ and was made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
